LNTH (Lantheus Holdings) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LNTH Lantheus Holdings Inc LNTH
80 GF Score
Price $104.27
GF Value $90.69
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lantheus Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Lantheus Holdings is: Low Risk: Strong fundamentals, worth long-term holding.

Lantheus Holdings  (NAS:LNTH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Lantheus Holdings Risk Assessment Related Terms

LNTH vs LQDA, HIMS, AMRX: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantheus Holdings Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's Risk Assessment falls into.


LNTH
80GF Score
Lantheus Holdings Inc LNTH
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lantheus Holdings (LNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of $104.27 is trading 15% above its estimated GF Value™ of $90.69. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for LNTH:

  • Risk Assessment:
  • GF Value™: $90.69 vs. price of $104.27 (15% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges 1LNTH:Italy0L8:Germany
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score

Get the complete analysis for LNTH

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$104.27
Price
$90.69
GF Value